PMID- 30820593
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1432-1440 (Electronic)
IS  - 0946-2716 (Linking)
VI  - 97
IP  - 4
DP  - 2019 Apr
TI  - Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
PG  - 463-472
LID - 10.1007/s00109-019-01761-5 [doi]
AB  - Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of 
      relapsing-remitting multiple sclerosis (RRMS). However, details regarding its 
      mode of action are still emerging. It is believed that the mode of action of DMF 
      involves both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent 
      and independent pathways, which lead to an anti-inflammatory immune response due 
      to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this 
      review, we will focus on the molecular and signaling effects of DMF that lead to 
      changes in peripheral immune cell composition and function, alteration in CNS 
      cell-specific functions, and effect on the blood-brain barrier.
FAU - Yadav, Sudhir Kumar
AU  - Yadav SK
AD  - Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, 
      NJ, 08854, USA.
FAU - Soin, Devika
AU  - Soin D
AD  - Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, 
      NJ, 08854, USA.
FAU - Ito, Kouichi
AU  - Ito K
AD  - Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, 
      NJ, 08854, USA.
FAU - Dhib-Jalbut, Suhayl
AU  - Dhib-Jalbut S
AD  - Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, 
      NJ, 08854, USA. jalbutsu@rwjms.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190228
PL  - Germany
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (NF-E2-Related Factor 2)
RN  - FO2303MNI2 (Dimethyl Fumarate)
SB  - IM
MH  - Animals
MH  - Dimethyl Fumarate/pharmacology/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology/*therapeutic use
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology
MH  - NF-E2-Related Factor 2/immunology
MH  - Th2 Cells/drug effects/immunology
OTO - NOTNLM
OT  - Dimethyl fumarate
OT  - Immunomodulation
OT  - Neuroprotection
OT  - Nuclear factor erythroid-derived 2-related factor
OT  - Relapsing-remitting multiple sclerosis
EDAT- 2019/03/02 06:00
MHDA- 2020/06/23 06:00
CRDT- 2019/03/02 06:00
PHST- 2018/12/08 00:00 [received]
PHST- 2019/02/19 00:00 [accepted]
PHST- 2019/02/15 00:00 [revised]
PHST- 2019/03/02 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2019/03/02 06:00 [entrez]
AID - 10.1007/s00109-019-01761-5 [pii]
AID - 10.1007/s00109-019-01761-5 [doi]
PST - ppublish
SO  - J Mol Med (Berl). 2019 Apr;97(4):463-472. doi: 10.1007/s00109-019-01761-5. Epub 
      2019 Feb 28.